Globus Medical Inc. Class A Common Stock vs Marqeta Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Marqeta Inc trades at $18.1 (market cap $1.93B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5.3× Marqeta Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Marqeta Inc for 44 Days on average.
| GMED | MQ | |
|---|---|---|
Market Cap | $10.25B | $1.93B |
Volume | 1,108,124 | 915,027 |
Sector | Health | Technology |
52-Week High | $96.82 | $20.32 |
52-Week Low | $58.33 | $15.04 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $9.76B | $1.25B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Marqeta (MQ) trades at $18.18, down 0.6% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 showing 17% net revenue growth and GAAP profitability. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. Cash flow turned positive in 2025 at $86.42M, a significant improvement from prior years' losses.
Outlook is mixed: strong revenue growth and product initiatives support upside, but high P/E of 206.22 and thin net margin of 1.53% pose valuation risks. Analyst consensus is cautious with a $11.38 price target, well below current levels. Key risks include contract renewals in Q3 2026 and competitive pressures in fintech.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →